State Street Corp Sells 71,036 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

State Street Corp lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,946,273 shares of the specialty pharmaceutical company's stock after selling 71,036 shares during the period. State Street Corp owned 3.22% of Jazz Pharmaceuticals worth $216,834,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in JAZZ. Wealth Enhancement Advisory Services LLC grew its position in shares of Jazz Pharmaceuticals by 27.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the specialty pharmaceutical company's stock worth $379,000 after buying an additional 768 shares during the period. Envestnet Portfolio Solutions Inc. boosted its stake in Jazz Pharmaceuticals by 13.9% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 2,753 shares of the specialty pharmaceutical company's stock worth $294,000 after acquiring an additional 335 shares during the last quarter. Swedbank AB bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $106,936,000. Fiduciary Financial Group LLC acquired a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $242,000. Finally, Ellsworth Advisors LLC increased its stake in Jazz Pharmaceuticals by 3.9% in the second quarter. Ellsworth Advisors LLC now owns 37,181 shares of the specialty pharmaceutical company's stock valued at $3,968,000 after purchasing an additional 1,401 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. Needham & Company LLC reiterated a "buy" rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday. Royal Bank of Canada restated an "outperform" rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a report on Monday, November 18th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $177.00.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $3.40 during mid-day trading on Thursday, reaching $124.12. 447,739 shares of the company were exchanged, compared to its average volume of 666,486. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The stock has a market capitalization of $7.50 billion, a P/E ratio of 17.63, a P/E/G ratio of 1.04 and a beta of 0.57. The company's 50-day simple moving average is $116.81 and its 200-day simple moving average is $111.91. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,753 shares of company stock worth $816,289 over the last three months. Insiders own 4.20% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.